Aktienanalyse zu Regenxbio Inc (RGNX)RGNXRegenxbio Inc

REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address an array of diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). It is developing RGX-121 for the treatment of Mucopolysaccharidosis type II (MPS II), and RGX-111 to treat Mucopolysaccharidosis Type I. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Regenxbio Inc (RGNX) is a good buy right now, primarily due to its recent clinical trial success where 93% of patients achieved significant microdystrophin expression, indicating strong potential for FDA approval. The current price of $8.07 is significantly below the analyst price target of $22 from Mizuho, suggesting a potential upside of 173%. Additionally, the stock has seen a recent 5-day change of +8.61%, indicating positive momentum. However, a key risk is the clinical hold on RGX-121, which has led to a downgrade in price targets from several analysts, with H.C. Wainwright reducing theirs from $23 to $21.

5 analysts cover RGNX: 5 rate it Buy, 0 Hold and 0 Sell. The average price target is 29.71.